Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

Código QR

Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

BackgroundImmune checkpoint inhibitors (ICIs) have shown promising anti-tumor activity in multiple malignances including breast cancer. However, the responses can vary. This meta-analysis was conducted to evaluate the efficacy and safety profile of adding ICIs to neoadjuvant chemotherapy against tri...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yunhai Li, Lei Xing, Fan Li, Hong Liu, Lu Gan, Dejuan Yang, Mengxue Wang, Xuedong Yin, Hongyuan Li, Guosheng Ren
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	triple-negative breast cancer (TNBC) neoadjuvant chemotherapy immune checkpoint inhibitors (ICI) pathological complete response meta-analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/495d767440f04a549b2f028fa8b85695
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
por: Yuanfang Xin, et al.
Publicado: (2021)

A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Bingqing Xia, et al.
Publicado: (2021)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
por: da Silva JL, et al.
Publicado: (2021)

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jesse Lopes da Silva, et al.
Publicado: (2021)

Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
por: Ana Julia Aguiar de Freitas, et al.
Publicado: (2021)

An Immune-Related Gene Prognostic Index for Triple-Negative Breast Cancer Integrates Multiple Aspects of Tumor-Immune Microenvironment
por: Xiaowei Wang, et al.
Publicado: (2021)

Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in Advanced Breast Cancer by Ultrasound and Clinicopathological Features Using a Nomogram
por: Hao Cui, et al.
Publicado: (2021)

Association of tumor‐infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer
por: Jin Hong, et al.
Publicado: (2021)

Therapeutic Effects of Dietary Soybean Genistein on Triple-Negative Breast Cancer via Regulation of Epigenetic Mechanisms
por: Manvi Sharma, et al.
Publicado: (2021)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zilin Zhang, et al.
Publicado: (2021)

Outcomes of neoadjuvant chemotherapy in resectable, borderline resectable and locally advanced pancreatic cancer
por: Kamil D. Dalgatov, et al.
Publicado: (2021)

Neoadjuvant Therapy Using Checkpoint Inhibitors before Radical Cystectomy for Muscle Invasive Bladder Cancer: A Systematic Review
por: Hadi SHSM, et al.
Publicado: (2021)

Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
por: Xupeng Bai, et al.
Publicado: (2021)

Molecular Classification of Breast Cancer Utilizing Long Non-Coding RNA (lncRNA) Transcriptomes Identifies Novel Diagnostic lncRNA Panel for Triple-Negative Breast Cancer
por: Hibah Shaath, et al.
Publicado: (2021)

Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer
por: Hongyuan Zhao, et al.
Publicado: (2021)

A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer
por: Du Y, et al.
Publicado: (2018)

Assessing Clinicopathological Features and Prognosis of Triple-Negative Breast Cancer Patients: A Single-Center Study in Turkey
por: Saliha Karagöz Eren, et al.
Publicado: (2021)

Neoadjuvant therapy strategies for advanced gastric cancer: Current innovations and future challenges
por: Zhi Zhu, et al.
Publicado: (2020)

A Comparison of Different Schemes of Neoadjuvant Chemotherapy Followed by Concurrent Chemotherapy and Radiotherapy for Locally Advanced Cervical Cancer: A Retrospective Study
por: Tian X, et al.
Publicado: (2021)

Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer
por: Hyder T, et al.
Publicado: (2021)

MicroRNA-223 is Associated with Resistance Towards Platinum-based Chemotherapy and Worse Prognosis in Indonesian Triple-negative Breast Cancer Patients
por: Purwanto I, et al.
Publicado: (2021)

Mechanisms behind prometastatic changes induced by neoadjuvant chemotherapy in the breast cancer microenvironment
por: Perelmuter VM, et al.
Publicado: (2019)

Characteristics and Risk Factors of Postoperative Complications in Gastric Cancer Patients Treated with Neoadjuvant Chemotherapy
por: SUN Chongyuan, et al.
Publicado: (2021)

Mirna21 Expression in the Breast Cancer Tumor Tissue is Independent of Neoadjuvant Chemotherapy
por: Sales ACV, et al.
Publicado: (2020)

Machine Learning-Based Radiomics Nomogram With Dynamic Contrast-Enhanced MRI of the Osteosarcoma for Evaluation of Efficacy of Neoadjuvant Chemotherapy
por: Lu Zhang, et al.
Publicado: (2021)

Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer
por: Rui He, et al.
Publicado: (2021)

Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
por: Phung HT, et al.
Publicado: (2020)

The Influence of Lymph Node Count on Oncological Outcome of Radical Cystectomy in Chemotherapy Pre-Treated and Chemotherapy-Naïve Patients with Muscle Invasive Bladder Cancer
por: Artur Lemiński, et al.
Publicado: (2021)

Influence of correction of nutritive deficiency on the effectiveness of neoadjuvant chemotherapy in patients with locally advanced gastric cancer
por: Nadezhda A. Brish, et al.
Publicado: (2021)

Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
por: Inna P. Ganshina, et al.
Publicado: (2021)

Factors associated with higher rate of Complete Pathologic Response after Long-Course Neoadjuvant Treatment for Locally Advanced Rectal Cancer Patients – Results from a retrospective cohort study focused on Inflammatory Indexes
por: Carlos Cerdan-Santacruz, et al.
Publicado: (2021)

A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin
por: Mitchell Clark, et al.
Publicado: (2021)

THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY
por: A. I. Chertkova, et al.
Publicado: (2018)

Survival landscape of different tumor regression grades and pathologic complete response in rectal cancer after neoadjuvant therapy based on reconstructed individual patient data
por: Jia-yi Li, et al.
Publicado: (2021)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Xue-lin Zou, et al.
Publicado: (2021)

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
por: Ze-Rui Zhao, et al.
Publicado: (2021)

Application of Gross Tissue Response System in Gastric Cancer After Neoadjuvant Chemotherapy: A Primary Report of a Prospective Cohort Study
por: Hua Yang, et al.
Publicado: (2021)

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)
por: Nieves Martinez Chanza, et al.
Publicado: (2021)

Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer
por: Xin Zheng, et al.
Publicado: (2021)

Intraoperative and postoperative outcomes of Harmonic Focus versus monopolar electrocautery after neoadjuvant chemotherapy in breast conservative surgery: a comparative study
por: Islam Khaled, et al.
Publicado: (2021)